Received Mar 17, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
No side effects or symptoms have been reported. No additional AE; a 48 year old female received one dose of GARDASIL 9 in January of 2026 (exact date unknown); This spontaneous report was received from a pharmacist and referred to a 48-year-old female patient. The patient's medical history, past medications, and concomitant medications were not reported. In January 2026 (exact date unknown), the patient received one dose of human papillomavirus 9-valent vaccine, recombinant (GARDASIL 9) suspension for injection, 0.5 ml (lot number, expiration date, route of administration, and anatomical location were not provided) administered as prophylaxis (Product administered to patient of inappropriate age). The reporter inquired about the patient receiving a second dose; however, the patient had not received it at the time of reporting. No side effects or symptoms have been reported. No Additional adverse event (AE). Batch/Lot number is being requested and will be submitted if received.